FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to c compounds having dual agonistic activity both against GLP-1 (glucagon-like peptide 1) and against GLP-2 (glucagon-like peptide 2) receptors.
EFFECT: acylated GLP-1/GLP-2 agonists according to the present invention can be used in medicine, in particular in the prevention or treatment of intestinal damage and dysfunction, body weight regulation and the prevention or treatment of metabolic dysfunction in humans.
19 cl, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS | 2018 |
|
RU2779314C2 |
| MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | 2020 |
|
RU2816492C2 |
| MODIFIED ANALOGUES OF GIP PEPTIDE | 2019 |
|
RU2817673C2 |
| IMPROVED PEPTIDE DRUGS FOR TREATMENT OF NASH AND OTHER DISORDERS | 2019 |
|
RU2790209C2 |
| ACYLATED DERIVATIVE OF GLP-1 | 2019 |
|
RU2773242C2 |
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
| PEPTIDIC INTERLEUKIN-23 RECEPTOR INHIBITORS FOR ORAL ADMINISTRATION AND USE THEREOF FOR TREATING INFLAMMATORY INTESTINAL DISEASES | 2015 |
|
RU2736637C2 |
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
